お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
971333

先端巨大症・巨人症:疫学的予測 (2029年まで)

Acromegaly and Gigantism - Epidemiology Forecast to 2029

出版日: | 発行: GlobalData | ページ情報: 英文 49 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.77円
先端巨大症・巨人症:疫学的予測 (2029年まで)
出版日: 2020年11月15日
発行: GlobalData
ページ情報: 英文 49 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

2019年現在、世界の主要7ヶ国における先端巨大症の受診済み有病者数 (15歳以上) は43,220人を記録しました。国別に見ると、米国が26,549人と最も多く、スペインが1,775人と最小となっています。

当レポートでは、世界の主要7ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、カナダ) における先端巨大症 (末端巨大症) および巨人症の発症状況と今後の見通しについて分析し、疾患の特徴や現在の有病者の発症状況、今後10年間の有病件数の動向見通し、男女別・年齢別・併存症の種類別などの詳細動向などを調査しております。

目次

第1章 目次

第2章 先端巨大症・巨人症:エグゼクティブサマリー

第3章 疫学

  • 疾患の背景事情
  • 危険因子と併存症
  • 世界の過去の動向
  • 予測手法
    • 情報源
    • 予測の前提条件と方法
    • 先端巨大症・巨人症の受診済み有病者数
    • 先端巨大症・巨人症の受診済み有病者数:マクロ腺腫を併発した場合
    • 先端巨大症・巨人症の受診済み有病者数:糖尿病を併発した場合
    • 先端巨大症・巨人症の受診済み有病者数:心血管疾患を併発した場合
    • 先端巨大症・巨人症の受診済み有病者数:高血圧を併発した場合
  • 先端巨大症の疫学的予測 (2019年~2029年)
    • 先端巨大症の受診済み有病者数
    • 先端巨大症の受診済み有病者数:男女別
    • 先端巨大症の受診済み有病者数:年齢別
    • 先端巨大症の受診済み有病者数:マクロ腺腫を併発した場合
    • 先端巨大症の受診済み有病者数:各種併存症を併発した場合
    • 巨人症の受診済み有病者数
    • 巨人症の受診済み有病者数:男女別
    • 巨人症の受診済み有病者数:年齢別
    • 巨人症の受診済み有病者数:マクロ腺腫を併発した場合
    • 巨人症の受診済み有病者数:各種併存症を併発した場合
  • 討論
    • 疫学的予測による考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for Acromegaly and Gigantism
  • Table 4: Global Consensus Criteria for the Diagnosis and Cure of Acromegaly

List of Figures

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of Acromegaly (N), Both Sexes, Ages ≥15 Years, 2019 and 2029
  • Figure 2: 7MM, Diagnosed Prevalent Cases of Gigantism (N), Both Sexes, All Ages, 2019 and 2029
  • Figure 3: 7MM, Diagnosed Prevalence of Acromegaly (%), Men and Women, Ages ≥15 Years, 2019
  • Figure 4: 7MM, Diagnosed Prevalence of Gigantism (%), Men and Women, All Ages, 2019
  • Figure 5: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of Acromegaly
  • Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Gigantism
  • Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acromegaly and Gigantism with Macroadenoma
  • Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acromegaly and Gigantism with Diabetes
  • Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acromegaly and Gigantism with Cardiovascular Disease
  • Figure 10: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acromegaly and Gigantism with Hypertension
  • Figure 11: 7MM, Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages ≥15 Years, N, 2019
  • Figure 12: 7MM, Diagnosed Prevalent Cases of Acromegaly by Sex, Ages ≥15 Years, N, 2019
  • Figure 13: 7MM, Diagnosed Prevalent Cases of Acromegaly by Age, Both Sexes, N, 2019
  • Figure 14: 7MM, Diagnosed Prevalent Cases of Acromegaly with Macroadenoma, Both Sexes, Ages ≥15 Years, N, 2019
  • Figure 15: 7MM, Diagnosed Prevalent Cases of Acromegaly with Comorbidities, Both Sexes, Ages ≥15 Years, N, 2019
  • Figure 16: 7MM, Diagnosed Prevalent Cases of Gigantism, Both Sexes, All Ages, N, 2019
  • Figure 17: 7MM, Diagnosed Prevalent Cases of Gigantism, by Sex, All Ages, N, 2019
  • Figure 18: 7MM, Diagnosed Prevalent Cases of Gigantism by Age, Both Sexes, N, 2019
  • Figure 19: 7MM, Diagnosed Prevalent Cases of Gigantism with Macroadenoma, Both Sexes, All Ages, N, 2019
  • Figure 20: 7MM, Diagnosed Prevalent Cases of Gigantism with Comorbidities, Both Sexes, All Ages, N, 2019
目次
Product Code: GDHCER256-20

Acromegaly and gigantism are rare disorders of the pituitary gland, characterized by the hypersecretion of growth hormone (GH). In 98% of the cases of acromegaly and gigantism, the hypersecretion of GH results from a benign GH- secreting pituitary adenoma (Sesmilo, 2013). A common sign of acromegaly is enlarged hands and feet, and the disease can also cause gradual changes in the shape of the face, such as a protruding lower jaw and brow, an enlarged nose, thickened lips, and wider spacing between the teeth. Progression of acromegaly can result in major health problems such as diabetes mellitus, cardiovascular disease, hypertension, sleep apnea, carpal tunnel syndrome, and spinal cord compression (Mayo Clinic, 2019). While both acromegaly and gigantism are complications of uncontrolled GH levels, the presentations of the two hormonal diseases are very different; most notably, acromegaly occurs in adulthood and gigantism occurs during childhood (Eugster and Pescovitz, 1999). In 2019, the 7MM combined had 43,220 diagnosed prevalent cases of acromegaly in both sexes for ages 15 years and older.

The US accounted for the majority of these cases with 26,549 diagnosed prevalent cases, while Spain accounted for the fewest cases with 1,775 cases in 2019. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of acromegaly to 47,340 cases in 2029 in the 7MM at an Annual Growth Rate (AGR) of 0.95% during the forecast period. In 2019, the 7MM combined had 643 diagnosed prevalent cases of gigantism in both sexes for all ages. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of gigantism to 675 cases in 2029 in the 7MM at an AGR of 0.50% during the forecast period. Any change in the diagnosed prevalent cases of acromegaly and gigantism in the 7MM is attributable to changing population demographics and changing diagnosed prevalence rates in the respective markets.

Scope

  • The Acromegaly and Gigantism Report provides an overview of the risk factors, comorbidities, and the global and historical trends for acromegaly and gigantism in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acromegaly and gigantism segmented by sex and age (ages 15 years and above in acromegaly cases, and all ages in gigantism cases). Additionally, GlobalData epidemiologists estimated the cases of type of pituitary adenoma (macroadenoma) and comorbidities (cardiovascular disease, diabetes, and hypertension) among the diagnosed prevalent cases of acromegaly and gigantism in the 7MM.
  • The acromegaly and gigantism epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

  • The Acromegaly and Gigantism Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global acromegaly and gigantism market.
  • Quantify patient populations in the global acromegaly and gigantism market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for acromegaly and gigantism therapeutics in each of the markets covered.
  • Understand magnitude of type of pituitary adenoma and comorbidities of acromegaly and gigantism.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Acromegaly and Gigantism: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Diagnosed Prevalent Cases of Acromegaly and Gigantism
    • 3.4.4 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Macroadenoma
    • 3.4.5 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Diabetes
    • 3.4.6 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Cardiovascular Disease
    • 3.4.7 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Hypertension
  • 3.5 Epidemiological Forecast for Acromegaly, 2019-2029
    • 3.5.1 Diagnosed Prevalent Cases of Acromegaly
    • 3.5.2 Sex-Specific Diagnosed Prevalent Cases of Acromegaly
    • 3.5.3 Age-Specific Diagnosed Prevalent Cases of Acromegaly
    • 3.5.4 Diagnosed Prevalent Cases of Acromegaly with Macroadenoma
    • 3.5.5 Diagnosed Prevalent Cases of Acromegaly with Comorbidities
    • 3.5.6 Diagnosed Prevalent Cases of Gigantism
    • 3.5.7 Sex-Specific Diagnosed Prevalent Cases of Gigantism
    • 3.5.8 Age-Specific Diagnosed Prevalent Cases of Gigantism
    • 3.5.9 Diagnosed Prevalent Cases of Gigantism with Macroadenoma
    • 3.5.10 Diagnosed Prevalent Cases of Gigantism with Comorbidities
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.